Recombinant IL17A, IL17F (Bimekizumab Biosimilar) anticorps
Aperçu rapide pour Recombinant IL17A, IL17F (Bimekizumab Biosimilar) anticorps (ABIN7597558)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Research Grade Bimekizumab Biosimilar Antibody
-
Specificité
- CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
-
Purification
- Protein A or G purified from cell culture supernatant.
-
Pureté
- >95 % by SDS-PAGE.
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 6.17 mg/mL
-
Buffer
- 0.01M PBS, pH 7.4.
-
Stock
- 4 °C,-20 °C,-80 °C
-
Stockage commentaire
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
-
Date de péremption
- 12 months
-
-
- IL17A, IL17F (Bimekizumab Biosimilar)
-
Autre désignation
- Bimekizumab Biosimilar
-
Classe de substances
- Biosimilar
-
Sujet
- CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
-
UniProt
- Q16552, Q96PD4
-
Numéro CAS
- 1418205-77-2
Antigène
-